InflaRx Announces New Mechanistic Data Supporting Izicopan as Best-in-Class C5aR Inhibitor

On April 9, 2026, InflaRx N.V. announced new mechanistic in vitro data for izicopan, its orally administered small molecule C5a receptor (C5aR) inhibitor. The findings, derived from a Ki-based time-dependent inhibition (TDI) study, demonstrate that izicopan does not exhibit time-dependent inhibition of the CYP3A4 enzyme. This is a significant pharmacological differentiator, as CYP3A4 inhibition is a primary indicator of potential drug-drug interactions (DDIs) and liver toxicity. The study utilized midazolam and testosterone as probe substrates and found no evidence of inhibition even at high concentrations (up to 100 µM). These results support izicopan's potential as a best-in-class C5aR inhibitor with a favorable safety profile, particularly for patients requiring concomitant medications like corticosteroids. Izicopan has previously shown promising Phase 2a results in hidradenitis suppurativa and chronic spontaneous urticaria, demonstrating rapid reductions in inflammatory lesions and improved disease control. The company continues to position izicopan as a differentiated alternative to existing C5aR inhibitors.